Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 3/2017

01.03.2017 | Adis Drug Evaluation

Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus

verfasst von: Karly P. Garnock-Jones

Erschienen in: Drugs | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Saxagliptin/dapagliflozin fixed-dose combination tablets (Qtern®) are indicated in the EU for the improvement of glycaemic control in adults with type 2 diabetes mellitus (T2DM), either when treatment with metformin and/or a sulfonylurea plus a monocomponent of saxagliptin/dapagliflozin provides inadequate glycaemic control, or when the patient is already being treated with the free combination of saxagliptin + dapagliflozin. This narrative review summarizes pharmacological, efficacy and tolerability data relevant to the use of saxagliptin/dapagliflozin in this indication. The agents have complementary mechanisms of action, and saxagliptin/dapagliflozin fixed-dose combination tablets are bioequivalent to free combination of saxagliptin + dapagliflozin. In three phase III trials, saxagliptin + dapagliflozin + metformin was more effective at providing glycaemic control than saxagliptin + metformin or dapagliflozin + metformin in previously treated patients with T2DM and inadequate glycaemic control on metformin monotherapy or metformin plus one of the monocomponents. The combination is associated with decreased bodyweight and a low risk of hypoglycaemia. As the first dipeptidyl peptidase-4 (DPP-4) inhibitor/sodium-glucose co-transporter (SGLT2) inhibitor fixed-dose combination available in the EU for glycaemic control in patients with T2DM, saxagliptin/dapagliflozin is a useful new option in this setting.
Literatur
1.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429–42.CrossRefPubMed
2.
3.
4.
Scheen AJ. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol. 2016;12(12):1407–17.
5.
Bell DS. Combine and conquer: advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab. 2013;15(4):291–300.CrossRefPubMed
6.
European Medicines Agency. QTern® (saxagliptin hydrochloride/dapagliflozin propanediol monohydrate tablets): EU summary of product characteristics. 2016. http://​www.​ema.​europa.​eu. Accessed 16 Jan 2017.
7.
Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs. 2014;74(18):2191–209.CrossRefPubMed
8.
9.
Yang LP. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. Drugs. 2012;72(2):229–48.CrossRefPubMed
10.
Hansen L, Iqbal N, Ekholm E, et al. Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy. Endocr Pract. 2014;20(11):1187–97.CrossRefPubMed
11.
Ekholm E, Hansen L, Iqbal N, et al. Combined treatment with saxagliptin + dapagliflozin improves beta cell function and reduces insulin levels by increased insulin clearance [abstract no. 731]. Diabetologia. 2015;58(Suppl 1):S349.
12.
Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38(11):2009–17.CrossRefPubMed
13.
Matthaei S, Catrinoiu D, Celinski A, et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care. 2015;38(11):2018–24.CrossRefPubMed
14.
Rohwedder K, Elkholm E, Cook W, et al. Dual treatment with saxagliptin + dapagliflozin provides a similar increase in urinary glucose excretion with fewer genitourinary infections compared with dapagliflozin [abstract no. 1208-P]. Diabetes. 2015;64(Suppl 1):A312.
15.
Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38(3):376–83.CrossRefPubMed
16.
Vakkalagadda B, Vetter ML, Rana J, et al. Bioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects. Pharmacol Res Perspect. 2015;3(6):1–12.CrossRef
17.
Vakkalagadda B, Lubin S, Reynolds L, et al. Lack of a pharmacokinetic interaction between saxagliptin and dapagliflozin in healthy subjects: a randomized crossover study. Clin Ther. 2016;38(8):1890–9.CrossRefPubMed
18.
Boulton DW, Kasichayanula S, Keung CFA, et al. Simultaneous oral therapeutic and intravenous 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br J Clin Pharmacol. 2013;75(3):763–8.PubMedPubMedCentral
19.
20.
Mathieu C, Herrera Mamolejo M, Gonzalez Gonzalez JG, et al. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(11):1134–7.CrossRefPubMed
21.
Matthaei S, Aggarwal N, Garcia-Hernandez P, et al. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. Diabetes Obes Metab. 2016;18(11):1128–33.CrossRefPubMed
22.
Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26.CrossRefPubMed
23.
Ptaszynska A, Cohen SM, Messing EM, et al. Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’. Diabetes Ther. 2015;6(3):357–75.CrossRefPubMedPubMedCentral
24.
Warren H, Raison N, Dasgupta P. Pioglitazone and bladder cancer. BJU Int. 2016;118(1):16–7.CrossRefPubMed
25.
European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. CPMP/EWP/1080/00 Rev. 1. 2012. http://​www.​ema.​europa.​eu. Accessed 16 Jan 2017.
26.
Tkac I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care. 2016. doi:10.​2337/​dc15-1707.
27.
Abdul-Ghani M. Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes? Diabetes Care. 2015;38(3):373–5.CrossRefPubMed
28.
Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J. 2016;37(19):1526–34.CrossRefPubMedPubMedCentral
Metadaten
Titel
Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus
verfasst von
Karly P. Garnock-Jones
Publikationsdatum
01.03.2017
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 3/2017
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-017-0697-1

Weitere Artikel der Ausgabe 3/2017

Drugs 3/2017 Zur Ausgabe

Adis Drug Evaluation

Teduglutide: A Review in Short Bowel Syndrome

Therapy in Practice

Drug Therapy for Stable Angina Pectoris

Adis Drug Evaluation

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation

Review Article

The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis

Current Opinion

Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies

Review Article

Pharmacological Management of Chronic Pelvic Pain in Women